Categories
Tags
Authors: Abrams RM, Simpson DM, Navis A, Jette N, Zhou L PMID: 34766365 PMCID: PMC8661991 DOI: 10.1002/mus.27458 Abstract Introduction/aims: The development and persistence of neurological symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is referred to as "long-haul" syndrome. We aimed to determine whether small fiber neuropathy (SFN) was associated with SARS-CoV-2 infection. [...]
Categories: I-RECOVER Post-Vaccine
Authors: Winslow RL, Zhou J, Windle EF, Nur I, Lall R, Ji C PMID: 34737194 PMCID: PMC8646974 DOI: 10.1136/thoraxjnl-2021-218035 Abstract Background: Continuous positive airways pressure (CPAP) and high-flow nasal oxygen (HFNO) are considered 'aerosol-generating procedures' in the treatment of COVID-19. Objective: To measure air and surface environmental contamination with SARS-CoV-2 virus when CPAP and HFNO [...]
Categories: MATH+
Tags: COVID-19, SARS-CoV-2
Authors: Olajide O, Iwuanyanwu VU, Adegbola OD, Al-Hindawi AA PMID: 34709564 PMCID: PMC8551352 DOI: 10.1007/s12035-021-02593-6 Abstract In addition to respiratory complications produced by SARS‐CoV‐2, accumulating evidence suggests that some neurological symptoms are associated with the disease caused by this coronavirus. In this study, we investigated the effects of the SARS‐CoV‐2 spike protein S1 stimulation on [...]
Categories: I-RECOVER Post-Vaccine
Tags: Neuroinflammation, SARS-CoV-2
Authors: Tran HT, Gigl M, Le NP, Dawid C, Lamy E PMID: 34681279 PMCID: PMC8538008 DOI: 10.3390/ph14101055 Abstract To date, there have been rapidly spreading new SARS-CoV-2 "variants of concern". They all contain multiple mutations in the ACE2 receptor recognition site of the spike protein, compared to the original Wuhan sequence, which is of great [...]
Categories: I-CARE Early Covid, I-RECOVER Post-Vaccine
Tags: ACE2 protein, COVID-19, dandelion, SARS-CoV-2
Authors: Clough E, Chean KT, Inigo J, Tubbesing KE, Chandra D, Chaves L PMID: 34599743 PMCID: PMC8487226 DOI: 10.1007/s11481-021-10015-6 Abstract Emerging clinical data from the current COVID-19 pandemic suggests that ~ 40% of COVID-19 patients develop neurological symptoms attributed to viral encephalitis while in COVID long haulers chronic neuro-inflammation and neuronal damage result in a [...]
Categories: I-RECOVER Post-Vaccine
Auhtors: Clough E, Chean KT, Inigo J, Tubbesing KE, Chandra D, Chaves L PMID: 34599743 PMCID: PMC8487226 DOI: 10.1007/s11481-021-10015-6 Abstract Emerging clinical data from the current COVID-19 pandemic suggests that ~ 40% of COVID-19 patients develop neurological symptoms attributed to viral encephalitis while in COVID long haulers chronic neuro-inflammation and neuronal damage result in a [...]
Categories: Cancer Care
Tags: Mitochondria, SARS-CoV-2, Spike Protein
Ivermectin is a drug that has been shown to be active against coronavirus disease 19 (COVID-19) in previous studies. Healthcare personnel are highly exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, we decided to offer them ivermectin as a pre-exposure prophylaxis (PrEP) method.
Categories:
Tags: ivermectin, SARS-CoV-2
Authors: Kabinger F, Stiller C, Schmitzova J, Kokic G PMID: 34381216 PMCID: PMC8437801 DOI: 10.1038/s41594-021-00651-0 Abstract Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, [...]
Categories: I-CARE Early Covid
Tags: COVID-19, molnupiravir, SARS-CoV-2
Authors: Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BM PMID: 33961695 PMCID: PMC8136050 DOI: 10.1093/infdis/jiab247 Abstract Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concentrate in genomes of RNA viruses during viral replication. β-d-N4-hydroxycytidine (NHC, initial metabolite of molnupiravir) is >100-fold more active [...]
Categories: I-CARE Early Covid
Tags: molnupiravir, mutagenesis, SARS-CoV-2
Authors: Tomassetti F, Nuccetelli M, Sarubbi S, Gisone F, Ciotti M PMID: 34339963 PMCID: PMC8313542 DOI: 10.1016/j.intimp.2021.108013 Abstract The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high [...]
Categories: I-RECOVER Post-Vaccine
Tags: ACE2 protein, Antibodies, SARS-CoV-2